ArticleImmunity, inflammation and disease2025
Unraveling the Clinical and Molecular Landscape of Myocardial Infarction in Behçet's Syndrome: A Comprehensive Analysis.
Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unraveling the Clinical and Molecular Landscape of Myocardial Infarction in Behçet's Syndrome: A Comprehensive Analysis.Immunity, inflammation and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesBehçet's syndrome (BS) is a rare inflammatory disorder with life-threatening complications like myocardial infarction (MI), driven by vasculitis and immune-mediated thrombosis. This study unveils distinct clinical and molecular profiles in BS patients with MI, employing gene analysis and Weighted Gene Co-expression Network Analysis (WGCNA) to pinpoint critical pathways and therapeutic targets, enhancing diagnostic precision and treatment efficacy.
methodsA total of 2358 BS patients (25 with MI, 2333 without MI) were analyzed. Clinical characteristics were compared based on the cohort. Differential gene expression analysis was performed on four microarray datasets, by using GEO datasets, and WGCNA identified key gene modules. KEGG/GO enrichment revealed disease pathways, while diagnostic models (ROC curves, nomograms) evaluated predictive accuracy.
resultsBS patients with MI exhibited longer disease duration, higher smoking rates, and increased vascular and cardiac involvement. Gene analysis identified 605 BS- and 523 MI-related genes, with pathways linked to immune regulation and vascular remodeling. Three genes, TLR5, IL2RB, and KLRB1, showed strong diagnostic potential (AUC > 0.8). A nomogram integrating these genes achieved high predictive accuracy (AUC = 0.876).
conclusionsThis study reveals distinct clinical and molecular profiles in BS-associated MI, emphasizing inflammatory pathways and immune dysregulation. The findings provide a foundation for early diagnosis and personalized therapeutic strategies, advancing care for BS patients at risk for MI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.